Home > Insider Trading > Filing (0001104659-14-082018)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
890465	Nps Pharmaceuticals Inc	NPSP	Biological Products, (No Disgnostic Substances) (2836)	870439579

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1299691	J Joseph Rogus	550 Hills Drive Bedminster NJ 07921	Svp, Gbl Technical Operations	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-11-17	26,782	$3.34	46,933	No	4	M	Direct
Common Stock	Disposition	2014-11-17	26,782	$30.00	20,151	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Options (right to buy)	Disposition	2014-11-17	26,782	$0.00	26,782	$3.34

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
85,343		2020-02-19	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.18, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
On February 19, 2010, the reporting person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of the date of this filing, the performance criteria and the time-based criteria for 112,125 of these options has been satisfied. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.